Fedratinib Reduced Spleen Volume in Ruxolitinib-Resistant Myelofibrosis

Patients with myelofibrosis resistant or intolerant to ruxolitinib may have an alternative treatment option with the JAK2-selective inhibitor fedratinib, according to the results of a recent phase II study.

 Cancer Network

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.